Olema Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell OLMA and other ETFs, options, and stocks.About OLMA
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies.
CEOSean P. Bohen
CEOSean P. Bohen
Employees96
Employees96
HeadquartersSan Francisco, California
HeadquartersSan Francisco, California
Founded2006
Founded2006
Employees96
Employees96
OLMA Key Statistics
Market cap2.09B
Market cap2.09B
Price-Earnings ratio-14.67
Price-Earnings ratio-14.67
Dividend yield—
Dividend yield—
Average volume2.66M
Average volume2.66M
High today$28.14
High today$28.14
Low today$25.62
Low today$25.62
Open price$27.37
Open price$27.37
Volume2.46M
Volume2.46M
52 Week high$29.51
52 Week high$29.51
52 Week low$2.86
52 Week low$2.86
Stock Snapshot
Olema Pharmaceuticals(OLMA) stock is priced at $26.38, giving the company a market capitalization of 2.09B. It carries a P/E multiple of -14.67.
On 2025-12-10, Olema Pharmaceuticals(OLMA) stock traded between a low of $25.62 and a high of $28.14. Shares are currently priced at $26.38, which is +3.0% above the low and -6.3% below the high.
The Olema Pharmaceuticals(OLMA)'s current trading volume is 2.46M, compared to an average daily volume of 2.66M.
In the last year, Olema Pharmaceuticals(OLMA) shares hit a 52-week high of $29.51 and a 52-week low of $2.86.
In the last year, Olema Pharmaceuticals(OLMA) shares hit a 52-week high of $29.51 and a 52-week low of $2.86.
Analyst ratings
100%
of 9 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own OLMA. This list is generated using Robinhood data, and it’s not a recommendation.